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Absence of systemic oxidative stress and
increased CSF prostaglandin F2a in
progressive MS
ABSTRACT
Objective: We aimed to investigate the role of oxidative stress in the progression of multiple scle-
rosis (MS).
Methods: We determined by liquid chromatography–tandem mass spectrometry nonenzymatic
(F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2a
[PGF2a]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of
inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity
and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9;
osteopontin) and axonal damage (neurofilament light protein).
Results: Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2a were
significantly lower in patients with progressive disease, and decreased with increasing disability score
(ExpandedDisability Status Scale). In contrast, CSF concentrations of PGF2a, but not F2-isoprostanes,
were significantly higher in patients with progressive disease than OND controls (p , 0.01). The
content of PGF2a in CSF increased with disease severity (p 5 0.044) and patient age (p 5 0.022),
although this increase could not be explained by age. CSF PGF2a decreased with natalizumab and
methylprednisolone treatment andwas unaffected by the use of nonsteroidal anti-inflammatory drug in
secondary progressive MS. CSF PGF2a did not associate with validated CSFmarkers of inflammation
and axonal damage that themselves did not associate with the Expanded Disability Status Scale.
Conclusions: Our data suggest that MS progression is associated with low systemic oxidative
activity. This may contribute to immune dysregulation with CNS inflammation accompanied by
increased local cyclooxygenase-dependent lipid oxidation. Neurol Neuroimmunol Neuroinflamm
2016;3:e256; doi: 10.1212/NXI.0000000000000256
GLOSSARY
F2-IP5 F2-isoprostane;MS5multiple sclerosis; OND5 other neurologic disease; PGF2a5 prostaglandin F; ROS5 reactive
oxygen species; RRMS 5 relapsing-remitting multiple sclerosis.
Multiple sclerosis (MS) is usually relapsing-remitting at onset, but, with time, a majority of patients
convert to a secondary progressive disease course, for which current therapies are ineffective.
Recently, increased oxidative stress has been proposed as a pathogenic mechanism leading to pro-
gressive MS.1 However, a decrease in reactive oxygen species (ROS) derived from NADPH oxidase
2 has been associated with more severe experimental autoimmune encephalomyelitis, a model of
MS.2,3 Moreover, disease progression correlates with altered activity of ROS-producing immune
cells.4–6 Thus, changes in local and systemic oxidative stress are of interest for the transition into
progressive MS, and we hypothesize that low oxidative stress may promote such progression.
F2-isoprostanes (F2-IPs) are considered the gold-standard biomarker of in vivo oxidative
stress.7 They are formed predominantly via nonenzymatic oxidation of arachidonic acid
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(20:4). However, themost frequently determined
F2-IP (8-iso-PGF2a), can also be generated dur-
ing enzymatic oxidation of 20:4 to prostaglandin
F2a (PGF2a), involving cyclooxygenase.8 As cy-
clooxygenase is significantly induced during
inflammation, it can lead to incorrect biomarker
assignment and interpretation.8 Therefore, we
quantified the ROS-derived F2-IP and enzyme-
derived PGF2a in plasma and CSF of patients
with MS. We correlated these oxidation markers
with disease severity, patient age, and other clin-
ical measures. To explore whether CNS 20:4
oxidation changes with treatment, we also ana-
lyzed samples from 2 intervention studies of
patients with progressive MS treated with na-
talizumab or methylprednisolone.
METHODS Materials. Standards of F2-IP (5[R]-iPF2a-VI, 5
[S]-iPF2a-VI, 5-iPF2a-VI-d11, 8-iso-15[S]-PGF2a, 8-iso-15[R]-
PGF2a, 8-iso-15[S]-PGF2a-d4, and 15[R]-PGF2a), 15(S)-PGF2a
(hereafter referred to as PGF2a), 20:4, and 20:4-d8 were from
Cayman Chemicals (Ann Arbor, MI). Artificial CSF was from
Tocris Bioscience (Bristol, UK). Methanol (Fisher Scientific Inc.),
hexane, and ethyl acetate (Lab Scan) were of high-performance
liquid chromatography grade, and Bond Elut CertifyII SPE columns
were from Agilent Technologies (Santa Clara, CA). Other chemicals
were from Sigma, unless indicated otherwise.
Standard protocol approvals, registrations, and patient
consents. The ethical review boards of the Karolinska Institute
in Sweden (DN: 2009/2107-31-2) approved the study involving
62 patients with MS with a diagnosis according to the revised
McDonald criteria9 and a heterogeneous control group of 45
individuals with other neurologic diseases (ONDs) (see the table
for demographic data). These controls with ONDs displayed no
clinical and neuroradiologic features of MS and no signs of intra-
thecal inflammation as shown by the presence of oligoclonal
bands, increased immunoglobulin G index, or pleocytosis (higher
than upper normal limit, i.e., .5,000 cells/mL). The ethics
committee of the Capital Region of Denmark approved the 2
intervention studies with natalizumab10 (n 5 24) and methyl-
prednisolone11 (n5 30). Written informed consent was obtained
from all participants. Disease severity was assessed using the
Expanded Disability Status Scale score. CSF was collected during
diagnostic workup according to clinical routine,10,11 and for the
Swedish study, venous EDTA blood samples were collected at
the same time. Following centrifugation (15 minutes, 2,700g,
room temperature), the resulting plasma was stored at 280°C
until use. CSF mononuclear and polymorphonuclear cells
were determined by flow cytometry and albumin with an auto-
mated system (Beckman Coulter UniCel DxC 800 Pro). Che-
mokine CXCL13, matrix metalloproteinase-9, osteopontin,
and neurofilament light protein were determined using
corresponding ELISA kits.12 Coded samples were shipped
frozen on dry ice to Australia for liquid chromatography–
tandem mass spectrometric analysis of F2-IP and PGF2a.
Upon receipt, frozen samples were placed immediately at
280°C until analysis was performed blinded within 12
months. The Sydney Local Health District Ethics Review
Table Demographic data of patients and controls in the longitudinal study
Clinical/paraclinical measures RRMS SPMS PPMS OND
No. of participants 23 24 15 45
Mean age, y (range) 35.9 (21–52) 49.4 (33–62) 55 (35–70) 40.3 (19–82)
Female/male 19/4 15/9 7/8 30/15
Mean disease duration, y (range) 2.7 (1–12) 18.5 (9–37) 6.5 (1–17) NA
Median EDSS score (range) 1.5 (0–4.5) 5.75 (3.0–8.0) 4.0 (2.0–6.5) NA
Annualized relapse rate (range) 1.17 (0–4) 0.17 (0–1) 0 (0–0) NA
Previous DMT, % 13.0 50.0 6.7 2.2a
DMT at sample time point, % 13.0 20.8 0 2.2a
Mean IgG index (range) 0.93 (0.50–2.35) 0.85 (0.46–1.77) 0.92 (0.48–1.9) 0.50 (0.43–0.62)
Oligoclonal IgG bands (1/2/NA) 20/3/0 21/3/0 12/3/0 2/41/2
Mean CSF albumin quotient (range) 4.4 (2.6–7.6) 6.1 (2.4–12.0) 7.1 (3.1–12.2) 4.5 (2.5–11.2)
No. of brain MRI lesions, %
0–2 13 0 7 NA
3–5 13 0 0 NA
6–8 17 4 21 NA
‡9 57 96 72 NA
Median contrast-enhancing lesions (range) 1.0 (0–4) 0 (0–0) 0 (0–0) NA
Abbreviations: DMT 5 disease-modifying therapy; EDSS 5 Expanded Disability Status Scale; IgG 5 immunoglobulin G;
NA 5 not available; OND 5 other neurologic disease; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing-
remitting multiple sclerosis; SPMS 5 secondary progressive multiple sclerosis.
Age (in years) refers to the age at sampling time point.
aOne individual in the OND group used corticosteroid at the sampling time point and before.
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Committee (X12-0102 and HREC/12/RPAH/174) approved
use and analyses of all human samples.
Sample preparation. Frozen CSF and plasma samples were
thawed for 4 minutes at 25°C, then kept on ice at all times. A
solution of internal standards (1 ng 8-iso-15[S]-PGF2a-d4, 1 ng 5
[R/S]-iPF2a-d11, and 2.5 mg 20:4-d8 in nitrogen-purged ethanol)
was added to 1 mL of plasma or CSF and mixed briefly. Samples
were subjected to alkaline hydrolysis by adding 1 mL 1 M KOH in
methanol containing 0.005% butylated hydroxytoluene, purging
each tube with nitrogen, followed by incubation at 37°C for
30 minutes. Samples were acidified with 2 mL of sodium acetate
(100 mM, pH 4.6) and the pH-adjusted to 4.6 using HCl.
Following centrifugation (10 minutes, 800g, 4°C), the supernate
was applied to SPE columns preconditioned with 2 mL of
methanol, followed by 2 mL of sodium acetate containing 5%
(v/v) methanol, pH 7. Columns were washed with 2 mL of
methanol/water (1:1, v/v) followed by 2 mL of ethyl acetate/hexane
(1:3, v/v). Analytes were eluted with 2 mL of ethyl acetate/methanol
(9:1, v/v), evaporated to dryness under nitrogen, and reconstituted in
50 mL of 50% methanol containing 0.01% acetic acid.
Liquid chromatography–tandem mass spectrometry.
PGF2a, F2-IP, and 20:4 in CSF and plasma were quantified by
liquid chromatography–tandem mass spectrometry (QQQ 6490
mass spectrometer; Agilent Technologies) with an ESI source and
multiple-reaction monitoring in negative ionization mode. A Zorbax
Eclipse C18 column (2.13 50 mm, 1.8mm; Agilent Technologies)
was used for separation at a flow rate of 0.35 mL/min, with
a gradient of A: 0.01% acetic acid in water, and B: 100%
methanol. Solvent B was increased initially from 50% to 60% B
in the first 15 minutes, then to 90% at 15.1 minutes, 100% at
20 minutes, and held for 3 minutes before re-equilibration at 50%.
For quantification, specific ion pairs were monitored: 5-series F2-IP
m/z 353/ 115; 5-iPF2a-VI-d11 m/z 364/ 115; 15-series F2-IP
m/z 353/ 193; 15-F2t-IsoP-d4 m/z 357/ 197; 20:4 m/z 303
/ 205; 20:4-d8 m/z 311/ 213. Quantification was achieved by
peak area comparison with the corresponding internal standard,
using Mass Hunter software. Only peaks coeluting with internal
standard and with a signal-to-noise ratio of $3 (defined as limit
of detection) were quantified. Results were expressed as amount of
oxidized lipid per volume or 20:4 content. Samples in which F2-IP
and PGF2a were below detection limit were not considered
for statistical analyses, resulting in variable n-numbers for different
F2-IP and PGF2a. The linearity and reproducibility of the assay
was confirmed by spiking plasma or CSF before hydrolysis
with authentic standards of 5-iPF2a-VI and 15-F2t-IsoP (0.05–2.5
ng/mL) or 20:4 (0.1–100 mg/mL). Intra- and interday coefficients
of variation (calculated from the responses of the internal standards)
were 1.8%–12.6% and 6.4%–15.2% for the 5-series F2-IPs, and
3.1%–12.2% and 2.9%–13.5% for the 15 series F2-IPs,
respectively.
Statistical analyses. Statistical analyses were performed using
GraphPad Prism version 6.0 for Macintosh (San Diego, CA). For
comparison of median values between .2 groups, Kruskal-Wallis
test with Dunn posttest was used. Because this was an exploratory
study, no adjustment for multiple comparisons was made. Correlation
analyses were performed using Spearman ranked correlation at 95%
confidence interval. For the intervention studies, statistical significance
was determined by the Wilcoxon matched-pairs signed rank test.
RESULTS Plasma F2-IPs decrease with MS progression.
We first examined systemic oxidative stress in progres-
sive MS by measuring the concentrations of 20:4,
F2-IP, and PGF2a in plasma of controls with OND
and patients with MS at various disease stages. The
method used allowed for quantification of 4 series of
F2-IP (figure 1A). Because of the limited availability of
authentic standards required for unambiguous assign-
ment of chromatographic peaks, we restricted our anal-
ysis to F2-IP species for which standards were available
commercially (figure 1B).
Plasma concentrations of F2-IP and PGF2a were
significantly lower in patients with progressive MS
compared to patients with relapsing-remitting MS
(RRMS) and OND controls (figure 2). This was true
for individual 5- and 15-species and for the sum of
products detected for each IP series. The amount of
the oxidation products formed can be affected by the
concentration of substrate13; however, plasma 20:4
concentrations did not vary between controls with
OND and patients with MS (figure 2G). These re-
sults indicate that MS progression is not associated
with increased systemic oxidative stress.
PGF2a but not F2-IP is increased in CSF from patients
with progressive MS. We next determined 20:4 and
20:4 oxidation products in CSF from patients with
MS and OND controls. Concentrations of different
F2-IP species (figure 3, A–E) and 20:4 (figure 3G)
were comparable in controls and patients. However,
CSF of patients with progressive MS contained sig-
nificantly higher concentrations of PGF2a than CSF
of patients with RRMS and OND controls (figure
3F). Normalizing the F2-IP and PGF2a data to CSF
20:4 did not change the overall results, consistent
with the similar concentrations of 20:4 in controls
and patients with MS. These results indicate that
MS is associated with an increase in enzymatic oxi-
dation of 20:4 rather than general oxidative stress in
the CNS.
Associations among PGF2a, disease severity, CSF
biomarkers, and age. In CSF, the concentration of
PGF2a increased with disease severity assessed by
the Expanded Disability Status Scale score, irrespec-
tive of whether PGF2a was standardized to CSF vol-
ume (rs 5 0.280, p 5 0.044) (not shown) or
normalized to 20:4 (figure e-1A at Neurology.org/nn).
Such association was not observed for 8-iso-15(S)
PGF2a (figure e-1B) and other F2-IP (not shown).
In contrast to PGF2a, none of the validated CSF
biomarkers determined correlated with disease
severity (figure e-1, C–I). The CSF concentration
of PGF2a (ng/mg 20:4) increased with patient age
(figure e-1J), although it remained higher in
progressive patients compared with age-matched
controls with OND (figure e-1K). Also, CSF PGF2a
remained higher in patients with secondary progressive
MS taking nonsteroidal anti-inflammatory drugs
compared with OND controls (figure e-1L). PGF2a
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did not correlate significantly with any of the
biomarkers determined (figure e-2).
In plasma, the content of PGF2a and each indi-
vidual F2-IP species decreased with increasing disease
severity (figure e-3, A–F). Plasma PGF2a decreased
with patient age (figure e-3G) but it remained signif-
icantly lower in progressive patients compared with
age-matched OND controls (figure e-3H). As a result,
the CSF/plasma ratio of PGF2a and F2-IP (except for
8-iso-15[R] PGF2a) were higher in patients with MS
who had progressive disease compared with controls
with OND (figure e-3, I–N), despite a decrease in the
CSF/plasma ratio of 20:4 (figure e-3O). These data
suggest that the disease-associated increase in CSF
PGF2a originates from increased local enzymatic oxi-
dation of 20:4 rather than circulating PGF2a. This
interpretation is consistent with the absence of MS-
associated increase in the CSF/plasma albumin ratio
(figure e-3P).
Treatment effect on CSF lipid oxidation in progressive
MS. To assess whether lipid oxidation in CNS is
affected by current MS therapies, we determined
CSF F2-IP from patients with progressive MS treated
with natalizumab or methylprednisolone.10,11 F2-IPs
were affected variably by natalizumab: compared with
baseline, the contents of 5(R)-iPF2a, 5(S)-iPF2a,
8-iso-15(R)-PGF2a, and 8-iso-15(S)-PGF2a (figure 4,
A–D) decreased significantly following 60 weeks of
treatment, while 15(R)-PGF2a remained unchanged
(p 5 0.563; figure 4E). In contrast to nonenzymatic
15(R)-PGF2a, its corresponding stereoisomer and
enzymatic product, 15(S)-PGF2a, was significantly
decreased after treatment compared with baseline
(p 5 0.002; figure 4F). CSF concentrations of
20:4 did not vary significantly between baseline
and treatment (data not shown).
We repeated the above analyses in a separate set of
CSF samples from patients with progressive MS at
baseline and 60 weeks after treatment with methyl-
prednisolone.11 In this cohort of 23 patients, PGF2a
was detected in CSF samples of only 7 patients. In all
of these patients, methylprednisolone treatment also
significantly decreased PGF2a (p 5 0.031) without
changing the content of 20:4 (p 5 0.819). Similar to
Figure 1 Arachidonic acid (20:4) oxidation pathways
(A) General structures of the 4 series of F2-isoprostanes formed from 20:4 via radical (R) mediated oxidation. (B) Chemical
structures of the 20:4 oxidation products studied (B.a–B.f) and corresponding heavy isotope-labeled internal standards (B.g
and B.h). Compounds B.a–B.e are formed via nonenzymatic oxidation of 20:4, whereas B.f is formed enzymatically and
nonenzymatically.
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the situation with natalizumab, CSF F2-IPs were gen-
erally but not consistently lower at 60 weeks com-
pared with baseline, and this did reach statistical
significance only in the case of 8-iso-15(S)-PGF2a
(p 5 0.031). Together, these results suggest that
enzymatic lipid oxidation in CNS of progressive
MS is decreased by modulating the enzymatic activity
of inflammatory cells (with methylprednisolone) or
blocking their migration into the CNS (with
natalizumab).
DISCUSSION There are 2 main new findings in the
present study. First, compared with OND controls,
the concentration of PGF2a in CSF is elevated in
participants with progressive MS, and it increases
with disease progression while it is decreased by
treatment with natalizumab and methylprednisolone.
The disease-associated increase in PGF2a does not
simply reflect the heightened state of inflammation
and breakdown of the blood–brain barrier typical of
RRMS.14 Rather, it may represent pathologic
responses to CNS resident cells, as disease severity
did not correlate with CSF inflammatory cells and
biomarkers, or the albumin ratio. Together, the data
suggest that cyclooxygenase-mediated formation of
PGF2a may have a role in the pathogenesis of
progressive MS.
Second, plasma concentrations of F2-IP were sig-
nificantly lower in patients with progressive MS than
OND controls and patients with RRMS. This is con-
sistent with progressive MS being a consequence
of impaired NADPH oxidase-dependent oxidative
Figure 2 Decrease in F2-isoprostanes in blood plasma of patients with progressive MS
Results show values (ng/mL plasma) for the specific 5-series products 5(R)-iPF2a (A) and 5(S)-iPF2a (B), the specific 15-series products 8-iso-15(R)-PGF2a (C),
8-iso-15(S)-PGF2a (D), and 15(R)-PGF2a (E), as well as the enzymatic product 15(S)-PGF2a (F) and the precursor arachidonic acid, 20:4 (G). Patients were
classified as follows: ONDs (n5 45), RRMS (n5 23), SPMS (n5 24), and PPMS (n5 15). A heterogeneous group of individuals with ONDs (n5 45) were used
as control with the following diagnoses: unspecified sensory disturbances (n 5 18), different psychological symptoms (n 5 6), dizziness (n 5 1), unspecified
headache (n5 4), chronic idiopathic fatigue (n5 1), balance disturbance (n5 1), visual disturbance (n5 2), muscle diseases (n5 2), trigeminal neuralgia (n5 1),
ulcerative colitis (n5 1), spinal stenosis (n5 1), stroke (n5 1), polymyositis (n5 1), postcommotion syndrome (n5 1), unspecific sarcoidosis (n5 1), hypokalemia
(n 5 1), hypesthesia (n 5 1), and Bechterew disease (n 5 1). Data show results for individual participants and mean 6 SEM. Statistical significance was
determined by the Kruskal-Wallis multiple comparison test. **p , 0.01, ***p , 0.001, ****p , 0.0001. MS 5 multiple sclerosis; OND 5 other neurologic
disease; PPMS 5 primary progressive MS; RRMS 5 relapsing-remitting MS; SPMS 5 secondary progressive MS.
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dampening of systemic immune activation.2,3 A
potential implication of these findings is that the
use of antioxidants may be counterproductive, and
that instead agents increasing NADPH oxidase activ-
ity may be worth considering.
Although not commonly recognized, our observa-
tion of increased CSF PGF2a in patients with pro-
gressive MS is in agreement with previous reports.
Thus, cyclooxygenase-2 is expressed in CD641 mac-
rophages/microglia in actively demyelinating human
lesions15 and in damaged or apoptotic oligodendro-
cytes.16 Cyclooxygenase-derived products in addition
to PGF2a (PGE2, PGI2, and PGD2) are elevated in
the CSF of patients with MS17 and animal models of
the disease.18 Moreover, cyclooxygenase inhibition
improves MS symptoms in models of the disease.19
The synthesis of prostaglandins is complex,20 with
their biological effects mediated via specific cellular
receptors. Our findings, combined with previous
reports, suggest inhibition of prostaglandin synthesis
or their action as a potential drug target(s) for the
treatment of MS. Because selective cyclooxygenase
inhibitors can have severe side effects,21 a better
understanding of the processes that link elevated
CSF PGF2a to MS is required to identify appropriate
therapeutic targets to treat MS.18
In contrast to previous reports of increased oxida-
tive stress in patients with MS,22,23 we found no evi-
dence for MS being associated with an increase in
CSF F2-IP, considered the “gold standard” for the
assessment of in vivo oxidative stress.7 Consistent
with our findings, others24,25 also reported no signif-
icant difference between patients with MS and con-
trols in their CSF content of 8,12-iPF2a-VI (5-series
F2-IP), determined by mass spectrometry. However,
an increase in the CSF concentration of 8-iso-15(S)-
PGF2a was reported in the CSF of patients with MS
with F2-IP determined by ELISA.26–28 We attribute
Figure 3 Concentrations of F2-isoprostane in CSF of controls with OND (n 5 33) and patients with multiple sclerosis who had different
disease courses
Disease courses included RRMS (n5 19), SPMS (n5 31), and PPMS (n5 25). Results show values (ng/mL CSF) for the specific 5-series products: 5(R)-iPF2a
(A) and 5(S)-iPF2a (B); the specific 15-series products: 8-iso-15(R)-PGF2a (C), 8-iso-15(S)-PGF2a (D), 15(R)-PGF2a (E), and 15(S)-PGF2a (F), as well as
arachidonic acid (G). Red symbols: second KI batch; black symbols: third KI batch; blue symbols: baseline samples from the Danish NAPMS Study. Data
are shown for individuals and as means 6 SEM. Statistical significance was determined by the Kruskal-Wallis multiple comparison test. *p , 0.05. OND 5
other neurologic disease; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing-remitting multiple sclerosis; SPMS 5 secondary progressive
multiple sclerosis.
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these apparent discrepancies to differences in the
methods used to determine F2-IP. It is well known
that results from ELISA are not directly comparable
to those determined by mass spectrometry–based as-
says,29 with the former being less specific and com-
monly yielding higher values for 8-iso-15(S)-PGF2a
than mass spectrometry–based assays. Thus, our find-
ings are overall consistent with the literature and
strongly suggest that oxidative stress is not increased
in the CSF of patients with MS, and it does not
appear to have a role in disease progression. While
our study did not detect an increase in CSF F2-IP in
patients with MS, it does not exclude the possibility
that localized oxidative stress and damage to brain
tissue contribute to the lesions observed in patients
with MS.30
MS lesions are thought to arise as a result of the
migration of immune cells through the blood–brain
barrier, resulting in an inflammatory cascade that
leads to myelin loss, axonal damage, and neuronal
death.31 Binding of leukocytes a4-integrin to
VCAM-1 on the vascular endothelium facilitates
the migration of leukocytes across the blood–brain
barrier.32 The humanized a4-integrin monoclonal
antibody natalizumab blocks the recruitment of cir-
culating immune cells to the CNS33 and it has
recently been shown to reduce intrathecal inflamma-
tion and tissue damage in patients with progressive
MS.11 The observed decrease in enzymatic and some
nonenzymatic markers of 20:4 oxidation in the CSF
after natalizumab treatment suggests that intrathecal
pathogenic events are triggered by systemic immune
cells entering the CNS and this may be amenable to
treatment. Consequently, the reduced lipid oxidation
following natalizumab treatment is driven by
decreased intrathecal inflammation. The finding of
decreased CSF PGF2a following treatment with the
glucocorticoid methylprednisolone34 is also impor-
tant since we found that treatment was associated
with clinical improvement as well as improvement
in magnetization transfer ratio measurements in brain
MRI studies.11 This may reflect a direct effect of
methylprednisolone on the biosynthesis of PGF2a
rather than a general inhibition of intrathecal inflam-
mation since we found little effect of monthly meth-
ylprednisolone pulse treatment on a panel of other
biomarkers in progressive MS.11 The lack of correla-
tion between CSF PGF2a and validated inflammatory
biomarkers, and the differences in their response to
treatments, further suggests that multiple pathologic
mechanisms coexist in patients with MS contributing
to the complexity of this disease.
Our results indicate the potential utility of CSF
PGF2a as a biomarker of progressive MS. However,
the causal role of any abnormal finding in MS, such as
an increase in CSF PGF2a, will need experimental
support because it can also represent events secondary
to the disease process, for example a reduced level of
physical activity resulting from ambulation handicap.
Currently used MRI biomarkers are adequate for
Figure 4 Natalizumab treatment decreases PGF2a in CSF of patients with secondary progressive MS and primary progressive MS
Results are shown for the specific F2-IP 5-series: 5(R)-iPF2a (n5 12) (A) and 5(S)-iPF2a (n5 7) (B); and the 15-series: 8-iso-15(R)-PGF2a (n5 10) (C), 8-iso-15
(S)-PGF2a (n 5 11) (D), and 15(R)-PGF2a (n 5 6) (E), as well as the enzymatic oxidation product 15(S)-PGF2a (n 5 10) (F), respectively, before (baseline) and
after treatment with natalizumab (60 weeks) with data expressed as ng/mL CSF. Data show results for individual participants and mean6 SEM. Open circle
symbols represent values at or below detection limit. Dotted line represents the average LOD for each product. Statistical significance was determined by
Wilcoxon matched-pairs signed rank test. LOD 5 limit of detection; MS 5 multiple sclerosis.
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patients with RRMS but do not reflect the complex
pathogenesis of progressive MS. Although mass
spectrometry–based determination of PGF2a is labor-
intense, the specificity and reproducibility of the
quantitative data for the 6 prostanoids investigated
(figure 1B), over several separate batches of analyses
and involving 3 independent cohorts of patients
from 2 different sites, cannot be achieved with other
laboratory methods.
The decrease in plasma concentration of several
types of F2-IP in patients with MS is important. If
replicated, plasma F2-IP could serve as a more easily
obtainable biomarker for progressive MS. The data
are consistent with rodent studies that imply a genetic
deficiency in NADPH oxidase–derived ROS to con-
tribute to progressive MS via inadequate oxidative
dampening of immune competent cells.2,3 Thus,
there is a possible role for regulation of the oxidative
burst in humans, and genetic characteristics may be
decisive in whether, how soon, and how serious the
development of progressive MS ensues. To date,
genetic studies have largely been restricted to inci-
dence of disease, while correlation with disease sever-
ity and progression remains to be determined.
This study shows that PGF2a is significantly
increased in the CSF of patients with progressive
MS and that this is associated with disease severity
and amenable to treatment, but independent of age.
Since PGF2a has biological activities, such as modu-
lation of immunologic effector cell functions35,36 and
vasoconstriction,37 our results warrant future studies
addressing whether cyclooxygenase-derived oxidation
products of 20:4, including PGF2a, contribute to MS
pathogenesis. In addition, the surprisingly low sys-
temic concentrations of F2-IP deserve further atten-
tion regarding potential mechanisms of disease
progression, its treatment, and in relation to their
use as systemic biomarker.
AUTHOR CONTRIBUTIONS
M. Lam: study design, analyses or interpretation of data, drafting or revis-
ing the manuscript. G. Maghzal: analyses or interpretation of data, draft-
ing or revising the manuscript. M. Khademi: study design or
conceptualization, analyses or interpretation of data, drafting or revising
the manuscript. F. Piehl: study design or conceptualization, analyses or
interpretation of data, drafting or revising the manuscript. R. Ratzer:
study design or conceptualization, drafting or revising the manuscript.
J. Romme Christensen: study design or conceptualization, analyses or
interpretation of data, drafting or revising the manuscript. F. Sellebjerg:
study design or conceptualization, analyses or interpretation of data,
drafting or revising the manuscript. T. Olsson: study design and concep-
tualization, analyses or interpretation of data, drafting or revising the
manuscript. R. Stocker: study design and conceptualization, analyses or
interpretation of data, drafting or revising the manuscript. All authors
accept responsibility for conduct of research and give final approval.
STUDY FUNDING
This work was supported by grants from the National Health and Med-
ical Research Council of Australia (1003484 and 1037879 to R.S.), the
Office of Health and Medical Research, NSW State Government, the
European Commission Directorate-General for Research & Innovation
(HEALTH-F2-2012-278611), the Swedish Research Council (F.P. and
T.O.), the Danish MS Society, the Danish Council for Strategic
Research, Brdr. Rønje Holding, the Lounkær Foundation, the AFA
Foundation, Knut and Alice Wallenberg Foundation, and the Swedish
Brain Foundation.
DISCLOSURE
M. Lam, G. Maghzal, and M. Khademi report no disclosures. F. Piehl
served on the data safety monitoring committee for Parexel/Chugai,
received research support from Biogen, Novartis, Genzyme. R. Ratzer
received travel funding from Biogen Idec, Genzyme. J. Christensen
served on the scientific advisory board for Biogen Idec, received travel
funding and/or speaker honoraria from Biogen, TEVA, Novartis, con-
sulted for Biogen, TEVA. F.T. Sellebjerg served on the scientific advisory
board for Biogen Idec, Genzyme, Merck Serono, Sanofi-Aventis, Teva,
Novo Nordisk, received travel funding and/or speaker honoraria from
Biogen, Bayer Schering, Genzyme, Merck Serono, Novartis, Sanofi-
Aventis, Schering-Plough, Teva, is a section editor for Multiple Sclerosis
and Related Disorders, consulted for Biogen Idec, received research sup-
port from Biogen Idec, Sanofi-Aventis, Novartis, Danish Strategic
Research Council, Danish Multiple Sclerosis Society, Lounkær Founda-
tion. T. Olsson served on the scientific advisory board for Merck Serono,
Biogen Idec, Genzyme/Sanofi-Aventis, Novartis, received speaker hono-
raria from Novartis, Biogen Idec, Sanofi-Aventis, Merck, Genzyme, Med-
Immune, was coeditor for Current Opinion in Immunology; received
research support from Merck, Biogen Idec, Sanofi-Aventis, Bayer, No-
vartis, AstraZeneca, The Swedish Research Council, Euratrans Neurinox,
CombiMS, Swedish Brain Foundation, AFA Foundation, Knut and Alice
Wallenberg Foundation, Genzyme, EURATrans. R. Stocker served on
the editorial board for Free Radical Biology & Medicine, Antioxidant Redox
Signaling, Redox Report, Redox Biology, Archives of Biochemistry and Bio-
physics, received research support from AstraZeneca, National Health and
Medical Research Council of Australia, Office of Health and Medical
Research, NSW State Government, Australia. Go to Neurology.org/nn
for full disclosure forms.
Received October 29, 2015. Accepted in final form May 17, 2016.
REFERENCES
1. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase
expression in active multiple sclerosis lesions in relation to
oxidative tissue damage and mitochondrial injury. Brain
2012;135:886–899.
2. Hultqvist M, Olofsson P, Holmberg J, Bäckström BT,
Tordsson J, Holmdahl R. Enhanced autoimmunity, arthri-
tis, and encephalomyelitis in mice with a reduced oxidative
burst due to a mutation in the Ncf1 gene. Proc Natl Acad
Sci USA 2004;101:12646–12651.
3. Holmdahl R, Sareila O, Pizzolla A, et al. Hydrogen per-
oxide as an immunological transmitter regulating autoreac-
tive T cells. Antioxid Redox Signal 2013;18:1463–1474.
4. Lassmann H, Bruck W, Lucchinetti CF. The immunopa-
thology of multiple sclerosis: an overview. Brain Pathol
2007;17:210–218.
5. Ratzer R, Sondergaard HB, Christensen JR, et al. Gene
expression analysis of relapsing-remitting, primary progres-
sive and secondary progressive multiple sclerosis. Mult
Scler 2013;19:1841–1848.
6. Romme Christensen J, Bornsen L, Ratzer R, et al. Sys-
temic inflammation in progressive multiple sclerosis in-
volves follicular T-helper, Th17- and activated B-cells
and correlates with progression. PLoS One 2013;8:
e57820.
7. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of
Oxidative Stress Study III. Effects of the nonsteroidal anti-
inflammatory agents indomethacin and meclofenamic acid
8 Neurology: Neuroimmunology & Neuroinflammation
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
on measurements of oxidative products of lipids in CCl4
poisoning. Free Radic Biol Med 2005;38:711–718.
8. van ’t Erve TJ, Lih FB, Kadiiska MB, Deterding LJ,
Eling TE, Mason RP. Reinterpreting the best biomarker
of oxidative stress: the 8-iso-PGF2a/PGF2a ratio distin-
guishes chemical from enzymatic lipid peroxidation. Free
Radic Biol Med 2015;83:245–251.
9. Polman CH, Reingold SC, Banwell B, et al. Diagnostic
criteria for multiple sclerosis: 2010 revisions to the McDo-
nald criteria. Ann Neurol 2011;69:292–302.
10. Romme Christensen J, Ratzer R, Börnsen L, et al. Natali-
zumab in progressive MS: results of an open-label, phase 2A,
proof-of-concept trial. Neurology 2014;82:1499–1507.
11. Ratzer R, Iversen P, Börnsen L, et al. Monthly oral meth-
ylprednisolone pulse treatment in progressive multiple
sclerosis. Mult Scler 2016;22:926–934.
12. Romme Christensen J, Börnsen L, Khademi M, et al. CSF
inflammation and axonal damage are increased and corre-
late in progressive multiple sclerosis. Mult Scler 2013;19:
877–884.
13. Halliwell B, Lee CY. Using isoprostanes as biomarkers of
oxidative stress: some rarely considered issues. Antioxid
Redox Signal 2010;13:145–156.
14. Lassmann H, van Horssen J, Mahad D. Progressive mul-
tiple sclerosis: pathology and pathogenesis. Nat Rev Neu-
rol 2012;8:647–656.
15. Rose JW, Hill KE, Watt HE, Carlson NG. Inflammatory
cell expression of cyclooxygenase-2 in the multiple sclerosis
lesion. J Neuroimmunol 2004;149:40–49.
16. Carlson NG, Rojas MA, Redd JW, et al. Cyclooxygenase-
2 expression in oligodendrocytes increases sensitivity to
excitotoxic death. J Neuroinflamm 2010;7:25.
17. Dore-Duffy P, Donaldson JO, Koff T, Longo M,
Perry W. Prostaglandin release in multiple sclerosis:
correlation with disease activity. Neurology 1986;36:
1587–1590.
18. Kihara Y, Matsushita T, Kita Y, et al. Targeted lipido-
mics reveals mPGES-1-PGE2 as a therapeutic target for
multiple sclerosis. Proc Natl Acad Sci USA 2009;106:
21807–21812.
19. Palumbo S, Toscano CD, Parente L, Weigert R, Bosetti F.
The cyclooxygenase-2 pathway via the PGE2 EP2 receptor
contributes to oligodendrocytes apoptosis in cuprizone-
induced demyelination. J Neurochem 2012;121:418–427.
20. Ueno N, Murakami M, Tanioka T, et al. Coupling
between cyclooxygenase, terminal prostanoid synthase,
and phospholipase A2. J Biol Chem 2001;276:34918–
34927.
21. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA,
Egger M. Risk of cardiovascular events and rofecoxib:
cumulative meta-analysis. Lancet 2004;364:2021–2029.
22. Ferretti G, Bacchetti T, Principi F, et al. Increased levels of
lipid hydroperoxides in plasma of patients with multiple
sclerosis: a relationship with paraoxonase activity. Mult
Scler 2005;11:677–682.
23. Fischer MT, Wimmer I, Hoftberger R, et al. Disease-specific
molecular events in cortical multiple sclerosis lesions. Brain
2013;136:1799–1815.
24. Mattsson N, Haghighi S, Andersen O, et al. Elevated
cerebrospinal fluid F2-isoprostane levels indicating oxida-
tive stress in healthy siblings of multiple sclerosis patients.
Neurosci Lett 2007;414:233–236.
25. Teunissen CE, Sombekke M, van Winsen L, et al.
Increased plasma 8, 12-iso-iPF2alpha-VI levels in relapsing
multiple sclerosis patients are not predictive of disease pro-
gression. Mult Scler 2012;18:1092–1098.
26. Greco A, Minghetti L, Sette G, Fieschi C, Levi G.
Cerebrospinal fluid isoprostane shows oxidative stress
in patients with multiple sclerosis. Neurology 1999;53:
1876–1879.
27. Mir F, Lee D, Ray H, Sadiq SA. CSF isoprostane levels are
a biomarker of oxidative stress in multiple sclerosis. Neurol
Neuroimmunol Neuroinflamm 2014;1:e21. doi: 10.1212/
NXI.0000000000000021.
28. Sbardella E, Greco A, Stromillo ML, et al. Isoprostanes in
clinically isolated syndrome and early multiple sclerosis as
biomarkers of tissue damage and predictors of clinical
course. Mult Scler 2013;19:411–417.
29. Proudfoot J, Barden A, Mori TA, et al. Measurement of
urinary F2-isoprostanes as markers of in vivo lipid
peroxidation-A comparison of enzyme immunoassay with
gas chromatography/mass spectrometry. Anal Biochem
1999;272:209–215.
30. Haider L, Fischer MT, Frischer JM, et al. Oxidative
damage in multiple sclerosis lesions. Brain 2011;134:
1914–1924.
31. Ffrench-Constant C. Pathogenesis of multiple sclerosis.
Lancet 1994;343:271–275.
32. Engelhardt B. The role of alpha 4-integrin in T lymphocyte
migration into the inflamed and noninflamed central nervous
system. Curr Top Microbiol Immunol 1998;231:51–64.
33. Bielekova B, Becker BL. Monoclonal antibodies in MS:
mechanisms of action. Neurology 2010;74(suppl 1):
S31–S40.
34. Schweingruber N, Reichardt SD, Luhder F,
Reichardt HM. Mechanisms of glucocorticoids in the con-
trol of neuroinflammation. J Neuroendocrinol 2012;24:
174–182.
35. Goldyne ME. Prostaglandins and the modulation of
immunological responses. Int J Dermatol 1977;16:
701–712.
36. Pelus LM, Strausser HR. Prostaglandins and the immune
response. Life Sci 1977;20:903–913.
37. Kauffman GL Jr, Whittle BJ. Gastric vascular actions of
prostanoids and the dual effect of arachidonic acid. Am J
Physiol 1982;242:G582–G587.
Neurology: Neuroimmunology & Neuroinflammation 9
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/NXI.0000000000000256
2016;3; Neurol Neuroimmunol Neuroinflamm 
Magda A. Lam, Ghassan J. Maghzal, Mohsen Khademi, et al. 
progressive MS
 inα2Absence of systemic oxidative stress and increased CSF prostaglandin F
This information is current as of June 30, 2016
2016 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 




including high resolution figures, can be found at:
Supplementary Material
 http://nn.neurology.org/content/suppl/2016/06/30/3.4.e256.DC1
Supplementary material can be found at: 
References
 http://nn.neurology.org/content/3/4/e256.full.html##ref-list-1















its entirety can be found online at:




Information about ordering reprints can be found online:
2016 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
